Abbott's Q1 Dip: Why Double-Digit Growth & Year-High Dividends Make It a Must-Watch

Abbott Laboratories (ABT) has faced a challenging year, with its stock declining by 22%. This performance contrasts with the broader S&P 500 healthcare sector, where many companies have maintained relatively flat valuations.

The company is slated to report its first-quarter earnings on April 16th. While revenue expectations for the upcoming quarter are currently modest, projections indicate a return to double-digit growth in the periods that follow. Despite short-term revenue forecasts, Abbott's strong financial foundation and substantial free cash flow generation are seen as robust enough to support continued annual dividend increases. Furthermore, the company's dividend yield has presently reached its highest point of the year.

Abbott Laboratories (ABT) currently holds an RS Score of 67.73, placing it in the 41.72 percentile within both its country and sector. The stock demonstrates strong performance in several key areas, with high scores in Valuation (89.54), Growth (91.25), Profitability (84.91), and EPS Revisions (83.00). However, its Momentum score is weaker at 10.83. Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.